Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sergey Vladimirovich Nedogoda
Assessment of Clinical and Economic Effectiveness of Alectinib for Patients With ALK+ Non-Small Cell Lung Cancer Without Previous Experience of Targeted Therapy
Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
Related publications
Economic Impact of Preventing Brain Metastases With Alectinib in ALK-positive Non-Small Cell Lung Cancer
Lung Cancer
Cancer Research
Oncology
Respiratory Medicine
Pulmonary
Chinese Perspectives on Clinical Efficacy and Safety of Alectinib in Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
OncoTargets and Therapy
Oncology
Pharmacology
Case Report of Non-Small Cell Lung Cancer With STRN-ALK Translocation: A Nonresponder to Alectinib
Journal of Nihon University Medical Association
How Should We Treat Alectinib-Refractory ALK-Positive Non–Small Cell Lung Cancer?
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
Journal of the Advanced Practitioner in Oncology
Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
Clinical Cancer Research
Cancer Research
Oncology
Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
A Decade of Targeted Therapy for Non-Small Cell Lung Cancer
Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China
PLoS ONE
Multidisciplinary
